Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model compared to 8.2 % in institutional database with asunercept plus standard of care in newly diagnosed glioblastoma multiforme patients

Written by Kirsten Ruehl on 1st June 2023. Posted in Client News.

• Previous
• Next